The estimated Net Worth of Jonathan Freve is at least $157 Thousand dollars as of 3 December 2021. Mr Freve owns over 4,000 units of Galecto stock worth over $157,440 and over the last 8 years he sold GLTO stock worth over $0.
Mr has made over 8 trades of the Galecto stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of GLTO stock worth $9,960 on 3 December 2021.
The largest trade he's ever made was buying 5,000 units of Galecto stock on 14 November 2019 worth over $15,200. On average, Mr trades about 1,333 units every 108 days since 2016. As of 3 December 2021 he still owns at least 12,000 units of Galecto stock.
You can see the complete history of Mr Freve stock trades at the bottom of the page.
Jonathan P. Freve CPA, CPA is the Chief Financial Officer at Galecto.
Mr CPA is 43, he's been the Chief Financial Officer of Galecto since . There are 3 older and 1 younger executives at Galecto. The oldest executive at Galecto Inc. is Prof. Bertil Lindmark M.D., Ph.D., 66, who is the Chief Medical Officer.
Jonathan's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong, and Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Galecto executives and other stock owners filed with the SEC include: